Caroline Robert.

Linette, M.D., Ph.D., David Hogg, M.D., Christian H. Ottensmeier, M.D., Ph.D.D., Christian Peschel, M.D., Ian Quirt, M.D., Joseph I. Clark, M.D., Jedd D. Wolchok, M.D., Ph.D., Jeffrey S. Weber, M.D., Ph.D., Jason Tian, Ph.D., Michael J. Yellin, M.D., Geoffrey M. Nichol, M.B., Ch.B., Axel Hoos, M.D., Ph.D., and Walter J. Urba, M.D., Ph.D.: Improved Survival with Ipilimumab in Patients with Metastatic Melanoma The incidence of metastatic melanoma has increased over the past three decades,1,2 and the death rate continues to go up faster compared to the rate with melanoma.3 The World Health Organization estimates that world-wide there are 66,000 deaths annually from skin cancer, with approximately 80 percent due to melanoma.4 In the usa alone, an estimated 8600 individuals died from melanoma in ’09 2009.1 The median survival of patients with melanoma who have distant metastases is less than 1 year.5,6 No therapy is approved beyond the first-line therapy for metastatic melanoma, and enrollment in a medical trial is the standard of caution.Related StoriesCHOP researchers delay symptoms, expand lifespan in animal model of Batten diseaseSingle gene variation might influence weight problems in children, adultsApoE4-carrying guys with Alzheimer's disease vulnerable to brain bleedsThe disease is the effect of a deficiency of LPL, the principal enzyme involved in the clearance of triglycerides from the plasma compartment. Humans who are deficient in LPL develop chronic pancreatitis, ultimately leading to diabetes mellitus. Currently, there is absolutely no specific treatment open to modulate the course of the disease other than a severe reduction of fat molecules.